COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Emerging efficacy data have led to the emergency use authorization or approval of COVID-19 vaccines in several countries worldwide. Most trials of COVID-19 vaccines excluded patients with active malignancies, and thus data on the safety, tolerability and efficacy of the vaccines in patients with can...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Aakash, Gainor, Justin F., Hegde, Aparna, Schram, Alison M., Curigliano, Giuseppe, Pal, Sumanta, Liu, Stephen V., Halmos, Balazs, Groisberg, Roman, Grande, Enrique, Dragovich, Tomislav, Matrana, Marc, Agarwal, Neeraj, Chawla, Sant, Kato, Shumei, Morgan, Gilberto, Kasi, Pashtoon M., Solomon, Benjamin, Loong, Herbert H., Park, Haeseong, Choueiri, Toni K., Subbiah, Ishwaria M., Pemmaraju, Naveen, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957448/
https://www.ncbi.nlm.nih.gov/pubmed/33723371
http://dx.doi.org/10.1038/s41571-021-00487-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957448/
https://www.ncbi.nlm.nih.gov/pubmed/33723371
http://dx.doi.org/10.1038/s41571-021-00487-z

Ejemplares similares